REGN Stock Summary and Trading Ideas (Regeneron Pharmaceuticals | NASDAQ:REGN)

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals trades on the NASDAQ stock market under the symbol REGN.

As of December 24, 2025, REGN stock price declined to $783.71 with 231,984 million shares trading.

REGN has a beta of 0.68, meaning it tends to be less sensitive to market movements. REGN has a correlation of 0.08 to the broad based SPY ETF.

REGN has a market cap of $82.37 billion. This is considered a Large Cap stock.

Last quarter Regeneron Pharmaceuticals reported $4 billion in Revenue and $11.83 earnings per share. This beat revenue expectation by $161 million and exceeded earnings estimates by $2.99.

In the last 3 years, REGN traded as high as $1,211.20 and as low as $476.49.

The top ETF exchange traded funds that REGN belongs to (by Net Assets): VTI, VOO, QQQ, IVV, SPY.

REGN has underperformed the market in the last year with a return of +10.2%, while SPY returned +16.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in REGN shares. However, REGN has outperformed the market in the last 3 month and 2 week periods, returning +36.0% and +7.9%, while SPY returned +4.7% and +0.7%, respectively. This indicates REGN has been having a stronger performance recently.

REGN support price is $770.04 and resistance is $800.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that REGN shares will trade within this expected range on the day.